ESMO 2022 | Phase I dose escalation of IMC-F106C – first PRAME × CD3 ImmTAC bispecific protein in solid tumors

Omid Hamid, MD, The Angeles Clinic and Research Institute, Santa Monica, CA, discusses the results of a Phase I dose-escalation study of IMC-F106C, the first PRAME x CD3 ImmTAC bispecific protein in solid tumors. IMC-F106C is the first T-cell receptor bispecific protein targeting CD3 and PRAME, the most broadly expressed cancer testis antigen, which is homogenously expressed in multiple tumors. In this trial, IMC-F106C was investigated in lung, ovarian and endometrial cancer. This novel agent is well tolerated and demonstrated durable RECIST partial responses and ctDNA response in patients highly expressing PRAME across multiple tumor types. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.